CoChat

Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Asian Men

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Exenatide, a treatment for type 2 diabetes, slows gastric emptying as part of its pharmacologic action and may alter the absorption of concomitant oral drugs. This open‐label, 2‐period, fixed‐sequence study evaluated the influence of exenatide coadministration on the pharmacokinetics and pharmacodynamics of warfarin, a narrow therapeutic index drug, in healthy men (N = 16). A single, 25‐mg oral dose of warfarin, with a standardized breakfast, was administered alone in period 1 and concomitantly with 10 μg exenatide subcutaneous twice daily in period 2. Exenatide did not produce significant changes in R‐ or S‐warfarin pharmacokinetics. Although there were minor reductions in warfarin anticoagulant effect, the ratios of geometric means for the area under the international normalized ratio (INR)–time curve from dosing until the time of the last measurable INR value or maximum‐observed INR response being 0.94 (0.93‐0.96) and 0.88 (0.84‐0.92), respectively, the magnitude and direction of these changes do not suggest a safety concern from this interaction.

Overview

Integrity signals

Registry

Crossref · 10.1177/0091270006291622

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 28 references

Research works printed but not linked: 3

  1. Reddy S, 2005, Clinical pharmacokinetics of exenatide in patients with type 2 diabetes, AAPS J, 7
  2. McCowen K, 2003, Degradation of AC2993 (synthetic exendin‐4) in mice, rat, rabbit and monkey kidney membrane preparations, Toxicologist, 72, 349
  3. Linnebjerg H, 2005, Exenatide pharmacokinetics in patients with mild to moderate renal dysfunction and end stage renal disease, Diabetes, 54

Cited by

See all 54

Metadata

Authors
Soon, D., Kothare, P. A., Linnebjerg, H., Park, S., Yuen, E., Mace, K. F., & Wise, S. D.
Affiliations
  • National University of Singapore (SG)
  • Eli Lilly (United States) (US)
  • Eli Lilly (United Kingdom) (GB)
Venue
The Journal of Clinical Pharmacology
Publisher
Wiley
Published
2006-10
Volume
46
Issue
10
Pages
1179-1187
ISSN
  • 0021-9754 (ISSN-L)
  • 0091-2700
  • 1552-4604
OpenAlex
W2003444892
Cited by
54
References
28
Citations by year
2026: 2 · 2025: 2 · 2024: 1 · 2020: 1 · 2019: 3 · 2018: 3 · 2017: 2 · 2016: 1 · 2015: 1 · 2014: 4 · 2012: 8
FWCI
5.19
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Keywords
exenatide, warfarin, drug-drug interactions, pharmacokinetics, pharmacodynamics, gastric emptying, oral drug absorption, anticoagulant activity, international normalized ratio, type 2 diabetes, narrow therapeutic index drugs
MeSH terms
Exenatide, Administration, Oral, Adult, Anticoagulants, Aryl Hydrocarbon Hydroxylases, Chromatography, Liquid, Dose-Response Relationship, Drug, Drug Interactions, Genotype, Haplotypes, Headache, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Nausea, Peptides, Mass Spectrometry, Venoms, Warfarin, Area Under Curve, International Normalized Ratio, Asian People, Cytochrome P-450 CYP2C9

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Asian Men. https://app.cochat.ai/papers/10.1177/0091270006291622
The paper
Soon, D., Kothare, P. A., Linnebjerg, H., Park, S., Yuen, E., Mace, K. F., & Wise, S. D. (2006). Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Asian Men. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270006291622

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.